Additionally, the statistically significant differences in APOA1 levels before and after treatment in patients achieving CR and PR confirmed that downregulation of APOA1 expression promotes DLBCL progression by reducing cholesterol efflux in tumor cells. This evidence concerns the gene APOA1 and diffuse large B-cell lymphoma.